Neprilysin Inhibitor-Angiotensin II Receptor Blocker Combination Therapy (Sacubitril/valsartan) Suppresses Atherosclerotic Plaque Formation and Inhibits Inflammation in Apolipoprotein E- Deficient Mice.

Sci Rep · 2019 · PMC6482143 · PMID 31019233

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

In addition, compared with the animals in the control group, we found a decreasing trend in the plaque lipid content of the mice treated with valsartan, although the difference was not statistically significant (Figs 2j and 4 , P > 0.05).

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.